-
公开(公告)号：USD1038380S1
公开(公告)日：2024-08-06
申请号：US29894912
申请日：2023-06-15
摘要： The file of this patent contains at least one drawing executed in color. Copies of this patent with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
FIG. 1 is a front perspective view illustrating a first exemplary embodiment of our ornamental design for an autoinjector with a purple removable cap.
FIG. 2 is a front elevational view of the first exemplary embodiment of our ornamental design for an autoinjector of FIG. 1, the rear elevational view being a mirror image thereof.
FIG. 3 is a right side elevational view of the first exemplary embodiment of our ornamental design for an autoinjector of FIG. 1, the left side elevational view being a mirror image thereof.
FIG. 4 is a bottom plan view of the first exemplary embodiment of our ornamental design for an autoinjector of FIG. 1.
FIG. 5 is a top plan view of the first exemplary embodiment of our ornamental design for an autoinjector of FIG. 1.
FIG. 6 is a front perspective view illustrating a second exemplary embodiment of our ornamental design for an autoinjector with a purple removable cap.
FIG. 7 is a front elevational view of the second exemplary embodiment of our ornamental design for an autoinjector of FIG. 6, the rear elevational view being a mirror image thereof.
FIG. 8 is a right side elevational view of the second exemplary embodiment of our ornamental design for an autoinjector of FIG. 6, the left side elevational view being a mirror image thereof.
FIG. 9 is a bottom plan view of the second exemplary embodiment of our ornamental design for an autoinjector of FIG. 6.
FIG. 10 is a top plan view of the second exemplary embodiment of our ornamental design for an autoinjector of FIG. 6.
FIG. 11 is a front perspective view illustrating a third exemplary embodiment of our ornamental design for an autoinjector with a removable cap.
FIG. 12 is a front elevational view of the third exemplary embodiment of our ornamental design for an autoinjector of FIG. 11, the rear elevational view being a mirror image thereof.
FIG. 13 is a right side elevational view of the third exemplary embodiment of our ornamental design for an autoinjector of FIG. 11, the left side elevational view being a mirror image thereof.
FIG. 14 is a bottom plan view of the third exemplary embodiment of our ornamental design for an autoinjector of FIG. 11.
FIG. 15 is a top plan view of the third exemplary embodiment of our ornamental design for an autoinjector of FIG. 11.
FIG. 16 is a front perspective view illustrating a fourth exemplary embodiment of our ornamental design for an autoinjector with a removable cap.
FIG. 17 is a front elevational view of the fourth exemplary embodiment of our ornamental design for an autoinjector of FIG. 16, the rear elevational view being a mirror image thereof.
FIG. 18 is a right side elevational view of the fourth exemplary embodiment of our ornamental design for an autoinjector of FIG. 16, the left side elevational view being a mirror image thereof.
FIG. 19 is a bottom plan view of the fourth exemplary embodiment of our ornamental design for an autoinjector of FIG. 16; and,
FIG. 20 is a top plan view of the fourth exemplary embodiment of our ornamental design for an autoinjector of FIG. 16.
The broken lines depict portions of the article that form no part of the claimed design.-
公开(公告)号：US20240092860A1
公开(公告)日：2024-03-21
申请号：US18332366
申请日：2023-06-09
发明人： Nibedita CHATTOPADHYAY , Eric POMA , Erin WILLERT
IPC分类号： C07K14/705 , A61P35/00 , C12N15/63
CPC分类号： C07K14/70521 , A61P35/00 , C12N15/63 , A61K38/00
摘要： The instant invention provides binding proteins (“CD38-binding proteins”) which each comprise (1) a CD38-binding region for cell-targeting and (2) a Shiga toxin A Subunit effector polypeptide (“Shiga toxin effector polypeptide”). The Shiga toxin effector polypeptide components of the CD38-binding proteins may comprise a combination of mutations relative to a wild-type Shiga toxin sequence providing (1) de-immunization and/or (2) a reduction in protease sensitivity; wherein each Shiga toxin effector polypeptide retains one or more Shiga toxin function, such as, e.g., stimulating cellular internalization, directing intracellular routing, catalytic activity, and/or potent cytotoxicity. The CD38-binding proteins may have one or multiple uses, e.g., the selective killing of a specific CD38-expressing cell-type; and more generally, for the diagnosis and treatment of cancers and disorders involving CD38-expressing cells, e.g., in CD38-positive hematopoietic cancers such as multiple myeloma.
-
公开(公告)号：US20230250449A1
公开(公告)日：2023-08-10
申请号：US17995211
申请日：2021-04-02
发明人： Nathan MOORE , Fabio FACHIN
IPC分类号： C12N15/86 , C12N15/87 , C12N5/0783
CPC分类号： C12N15/86 , C12N15/87 , C12N5/0636 , C12N2510/00 , C12N2740/15043
摘要： The present disclosure provides, among other things, a method of engineering genetically modified cells comprising, maintaining the cells in a collection chamber, contacting the cells with a fluid flow of a composition comprising viral or non-viral particles, thereby engineering genetically modified cells. The present disclosure also provides, among other things, a method of engineering genetically modified cells comprising, subjecting the cells to a centrifugal force, contacting the cells with a fluid flow of a composition comprising viral or non-viral particles, thereby engineering genetically modified cells.
-
公开(公告)号：US20230096620A1
公开(公告)日：2023-03-30
申请号：US17604324
申请日：2020-04-17
摘要： Provided herein are combination therapies comprising an alpha4beta7 inhibitor, e.g., an anti-alpha4beta7 antibody, e.g., vedolizumab, and an IL-23 inhibitor, e.g., an anti-IL-23 antibody.
-
公开(公告)号：US11596688B2
公开(公告)日：2023-03-07
申请号：US16455103
申请日：2019-06-27
IPC分类号： A61K39/00 , A61K39/395 , G01N33/53 , G01N33/68 , C07K16/28
摘要： The invention provides methods for treating patients with anti-α4β7 antibody comprising predicting outcome of the antibody therapy. The invention relates to the identification of patients who can respond to therapy comprising an anti-α4β7 antibody.
-
公开(公告)号：US20230043949A1
公开(公告)日：2023-02-09
申请号：US17655541
申请日：2022-03-18
IPC分类号： C07K16/28 , A61P1/00 , A61K31/496 , A61K39/395
摘要： The invention provides methods for the treatment of chronic pouchitis comprising administering an anti-α4β7 antibody, e.g., vedolizumab, to a human subject in need thereof.
-
公开(公告)号：US11498708B2
公开(公告)日：2022-11-15
申请号：US17051004
申请日：2019-04-29
摘要： Systems and methods for distributing a filling fluid are discussed. More particularly an exemplary filling system may include a reservoir holding a filling fluid for distribution. The filling system may also include a pump and filling nozzle fluidly coupled to the reservoir. A processor executes a filling module that when executed receives at least one input fluid property of the filling fluid and generates at least one set of operating parameters for controlling operation of the pump during a filling operation based at least in part on the fluid property. The generated set of operating parameters enable control of the pump to distribute the filling fluid through the filling nozzle, such that a fluid interface with a stable resting profile forms in the filling fluid in the filling nozzle adjacent to the nozzle opening after the filling fluid is distributed from the filling nozzle.
-
公开(公告)号：US20220233531A1
公开(公告)日：2022-07-28
申请号：US17433042
申请日：2020-02-27
IPC分类号： A61K31/506 , C07K16/28 , A61P35/00
摘要： The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer in patients in need thereof. The methods comprise administering to a patient in need a small ubiquitin-like modifier (SUMO) activating enzyme (SAE) inhibitor, such as [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate or a pharmaceutically acceptable salt, in combination with one or more checkpoint inhibitors. Also provided are medicaments for use in treating cancer.
-
9.发明授权公开(公告)号：US11268154B2
公开(公告)日：2022-03-08
申请号：US15772954
申请日：2016-11-04
IPC分类号： C12Q1/68 , C12Q1/6886 , G01N33/50 , G01N33/574 , A61K31/454 , A61K31/573 , A61K31/69 , A61P35/00 , A61K9/48
摘要： The present disclosure relates to methods for the treatment of multiple myeloma in patients who have one or more cytogenetic alterations. In particular, the disclosure provides methods for treatment of multiple myeloma in patients who have one or more cytogenetic alternations by administering to a patient a treatment regimen comprising a proteasome inhibitor or a pharmaceutically acceptable salt, stereoisomeric or tautomeric form thereof if said patient is identified as a likely responder to the treatment regimen by assessing the presence of said cytogenetic alterations.
-
公开(公告)号：US20210347888A1
公开(公告)日：2021-11-11
申请号：US17239010
申请日：2021-04-23
发明人： Daniel Tavares , Bianka Prinz , James Geoghegan
IPC分类号： C07K16/28
摘要： Antibodies, fragments thereof and fusion proteins that specifically bind to CD19, are described, as well as methods of making and using such antibodies. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases.
-
-
-
-
-
-
-
-
-
搜索结果
1591 条记录 (耗时 0.064 秒)
